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The formation of advanced glycation end products (AGEs),
in various tissues has been known to enhance immunoinflam-
matory reactions and local oxidant stresses in long standing
diabetes. Recently, AGEs have been reported to play a role
in neointimal formation in animal models of arterial injury.
We attempted to determine whether the serum levels of AGEs
are associated with coronary restenosis in diabetic patients.
Blood samples were collected from diabetic patients with
coronary artery disease undergoing stent implantation and the
serum levels of AGEs were analyzed by the fluorescent
intensity method. The development of in-stent restenosis (ISR)
was evaluated by a 6-month follow-up coronary angiography.
A total of 263 target lesions were evaluated, in 203 patients.
The ISR rate in the high-AGE (>170 U/ml) group (40.1%) was
significantly higher than in the low-AGE group ( 170 U/ml)
(19.6%) (p<0.001). Furthermore, multivariate analysis re-
vealed that a high level of serum AGEs is an independent risk
factor for the development of ISR (odds ratio, 2.659; 95% CI,
1.431-4.940; p=0.002). The serum levels of AGEs constitute
an excellent predictive factor for ISR, and should be one of
the guidelines for medical therapy and interventional strategy
to prevent ISR in diabetic patients.
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INTRODUCTION
Restenosis remains a significant limitation with
regard to percutaneous coronary intervention
(PCI). Up to 30% of patients treated with PCI de-
velop restenosis, and the restenosis rate is even
higher in diabetic patients.1 This is assumed to be
the result of neointimal formation, which is char-
acterized by an inflammatory reaction at the site
of injury, the migration and proliferation of vas-
cular smooth muscle cells, and the synthesis of ex-
cessive extracellular matrix.2 However, the exact
pathogenic mechanisms underlying the develop-
ment of exaggerated restenosis in diabetes remain
poorly understood. A recent report has indicated
that longstanding hyperglycemia leads to the
generation of AGEs (advanced glycation end pro-
ducts), the products of nonenzymatic glycation/
oxidation of proteins/lipids. The accumulation of
these compounds induces vessel wall memory
and vascular perturbation, culminating in the pro-
gression of atherosclerosis, and plaque instability.3
Moreover, in animal arterial stenosis studies,
AGEs have been implicated in neointimal forma-
tion. According to these reports, AGE receptor/
ligand interaction plays a key role in neointimal
formation after vascular injury, irrespective of
diabetes status. These findings suggest a novel
target for minimizing neointimal hyperplasia.
4-6
Other reports demonstrated that AGEs may
directly influence the structural integrity of the
vessel wall and underlying basement membrane,
in a receptor-independent manner.7,8 However,
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the role of AGEs with regard to restenosis in
human coronary artery disease (CAD) remains
unknown. Therefore, we attempted to determine
whether serum AGE levels are associated with
in-stent restenosis (ISR), and whether they can be
used as a predictor for the development of ISR in
diabetic patients.
MATERIALS AND METHODS
Subjects
A consecutive series of patients (n=203), all of
whom had symptomatic coronary artery disease
successfully treated with stenting, and had under-
gone follow-up angiography between March 1998
and August 2003 at Yongdong Severance Hos-
pital, was enrolled in this study. We applied the
new American Diabetes Association (ADA) criteria
for diagnosis of diabetes mellitus. All patients
were found to suffer from type 2 diabetes mel-
litus. The exclusion criteria of this study included
impaired renal function (Cr 2.0 mg/dl), lesions
with chronic total occlusion, saphenous vein
grafts, and failure to turn up for the follow-up
angiographic examination. For the purpose of
patient classification, acute coronary syndrome
was defined as either acute myocardial infarction,
or unstable angina. The body mass index (BMI)
was calculated as weight (kg)/height (m)2.
Percutaneous coronary intervention procedure
All patients received bolus unfractionated hepa-
rin injections (10,000 U) before procedures. The
patients were also given a daily dose of aspirin
(200 mg) before the procedure, which was con-
tinued indefinitely. Additional daily doses of
ticlopidine (500 mg) or clopidogrel (75 mg) were
administered for at least four weeks after PCI. The
intervention procedures employed the femoral
approach, with arterial introducers of size 6.5F.
All patients were treated with stenting using
balloon expandable, slotted tube, or modular
designed bare metal stents. The procedure was
considered to be successful if: 1) there were no
adverse events or the need for urgent coronary
surgery; 2) the quantitative coronary angiography
(QCA) estimated residual stenosis was < 30%,
and 3) TIMI 3 flow distally was observed imme-
diately after stent implantation.
Quantitative coronary angiography and the
follow-up examination
The lesion morphology examination was classi-
fied according to the modified American College
of Cardiology/American Heart Association grad-
ing system, as type A, B1, B2, or C.9 Complex
lesions were designated as type B or C lesions. We
also performed quantitative computer-assisted off-
line analysis of the angiogram, using the auto-
mated edge-detection system CMS (Medis Medi-
cal Imaging Systems, Nuenen, Netherlands). The
pre-PCI minimal lumen diameter (MLD), lesion
length, percentage of diameter stenosis, and post-
PCI MLD were also evaluated via QCA analysis.
Before discharge, all patients were advised to turn
up in six-months for an angiographic examina-
tion. After discharge, the patients were followed
up clinically at 2-month intervals. Within 6
months after PCI, patients exhibiting clinical re-
currence of the symptoms and angiographic ISR
were assigned to the ISR group. At the 6-month
follow-up angiography, ISR was defined as >
50% stent stenosis, as determined by QCA an-
alysis.
Analysis of lipid profiles
Total cholesterol was determined by the cho-
lesterol-oxidase method (Daiichi, Tokyo, Japan).
Low density lipoprotein (LDL)-cholesterol levels
were assessed via the direct enzymatic method,
using cholestest LDL (Daiichi, Tokyo, Japan). Trig-
lyceride levels were measured using the glycero-
phosphate oxidase with glycerol blanking method
(Asan, Seoul, Korea). High density lipoprotein
(HDL)-cholesterol levels were determined by the
direct method, using polyethylene glycol-modi-
fied enzymes. Hypercholesterolemia was defined
as an LDL-cholesterol level of more than 160 mg/
dl, low HDL-cholesterol as an HDL-cholesterol
level of less than 35 mg/dl, and hypertriglyceri-
demia as a triglyceride level of more than 200
mg/dl.
Measurements of the serum levels of AGEs
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Blood was collected from all patients immedia-
tely prior to initial coronary angiography. The
blood samples were transferred to tubes without
EDTA, and were centrifuged at 2000 rpm for 20
minutes. Serum was kept frozen at -70 , until as-
sayed for AGE serum levels. After melting, serum
samples (20 l) were mixed with 480 l of trichloμ μ -
roacetic acid (0.15 mol/l) in microcentrifuge tubes,
and 100 l of chloroform was added. The AGEμ
serum levels were determined by fluorescent
intensity method using a fluorescence spectropho-
tometer (F-2000 Hitachi Ltd., Tokyo, Japan) at an
emission wavelength of 440 nm, with an excitation
wave length of 370 nm. The samples were run in
triplicate, and peak height mode was used for
signal measurements. The intra-assay and inter-
assay coefficients of variation for the determina-
tion of AGEs were 7.9% and 10.8%, respectively.10
Statistical analysis
Statistical analyses were performed with SPSS
software (Version 11.0 for Windows, SPSS, Chi-
cago, Illinois). In order to avoid an arbitrary cutoff
point of the serum AGEs level for prediction of
ISR, we performed receiver operating characteris-
tics (ROC) analyses. Comparison of the continu-
ous variables between the subgroups was con-
ducted via Students t-test. Multivariate analysis
(logistic regression) was also performed, in order
to determine the parameters for the prediction of
angiographic ISR. All the tests were two-tailed,
and a p < 0.05 was considered to be significant.
RESULTS
Baseline and 6-month follow-up characteristics of
the patients
A total of 263 treated lesions from 203 consecu-
tive patients were analyzed in this study. The
AGE serum levels in the 203 patients measured in
this study ranged from 48.5 U/ml to 283.3 U/ml
(151.1 ± 56.5 U/ml, mean ± SD). We tentatively
classified these patients using ROC analysis (Fig.
1A). Patients with an AGE level of > 170 U/ml
were designated as the high-AGEs group, while
those with AGE levels of 170 U/ml were des-
ignated as the low-AGEs group. According to this
classification, the high- and low-AGEs groups
consisted of 85 patients (115 lesions) and 118
patients (148 lesions), respectively. The baseline
clinical characteristics of the two groups were
found to match well with regard to various para-
meters, other than the level of HbA1c and the
duration of diabetes (Table 1). The duration after
Fig. 1. (A) Receiver operating characteristics (ROC) curve of the serum levels of AGEs for the in-stent restenosis (ISR).
ROC area was 0.659; 95% CI 0.589 to 0.729; p<0.001. The cutoff point for levels of AGEs was 170.2 U/ml (sensitivity=0.619,
specificity=0.659). (B) ISR rate in the high-AGEs (> 170 U/ml) group was 40.1%, whereas values in the low-AGEs ( 170
U/ml) group were 19.6%. Difference of ISR rate between two groups was statistically significant (p < 0.001).
A B
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the initial diagnosis of diabetes was longer in the
high-AGEs group (8.9 ± 5.8 years) than in the
low-AGEs group (4.9 ± 4.3 years) (p < 0.001). The
level of HbA1c at baseline was higher in the
high-AGEs group (8.3 ± 1.7%) than in the low-
AGEs group (7.8 ± 1.5%) (p=0.008). Furthermore,
the serum levels of AGEs correlated significantly
with HbA1c (r=0.523, p=0.001) and the duration of
diabetes (r=0.415, p < 0.01). The quantitative
coronary angiography data obtained at the base-
line and immediately after the procedure were not
significantly different between the 2 groups (Table
2). At the 6-month follow-up, the level of HbA1c
was higher in the high-AGE group (8.1 ± 1.6%)
than in the low-AGE group (7.1 ± 1.4%) (p=0.024).
However, the difference between the level of
HbA1c in the ISR group (7.9 ± 1.3%) and that of
the non-ISR group (7.2 ± 1.2%) did not reach
statistical significance (p=0.234).
Level of serum AGEs and ISR
ROC analysis indicated that the serum level of
AGEs showed adequate accuracy for ISR. The
optimal cutoff point of AGEs was 170.2 U/ml.
ROC area was 0.659; 95% CI 0.589 to 0.729; p <
0.001 (sensitivity=0.619, specificity=0.659) (Fig.
1A). The 6-month follow-up angiographic findings
revealed that the overall ISR rate was 28.9%, and
the values in the high-AGEs (> 170 U/ml) group
were 40.1%, whereas the values in the low-AGEs
( 170 U/ml) group were 19.6%. The difference
with regard to the ISR rate between the two
groups was statistically significant (p < 0.001) (Fig.
1B).
Multivariate Analysis of risk factors for ISR
The multivariate analysis of the risk factors for
ISR demonstrated that a high level of serum AGEs
(> 170 U/ml) constitutes an independent risk
factor for the development of angiographic reste-
nosis. (Odds ratio, 2.659; 95% CI, 1.431 - 4.940;
p=0.002). Furthermore, the pure AGE levels can be
considered to be an independent risk factor for
ISR (odds ratio (OR), 1.008; 95% CI, 1.002-1.014; p=
0.008). This value, 1.008, represents the value of a
1 U/ml increase of the serum AGE level; small
vessel caliber (post MLD 3.0 mm) (OR, 2.346;
Table 1. Baseline Clinical Characteristics
Level of AGEs (U/ml)
p value
170 (n=118) > 170 (n=85)
Age (yrs)
Male
Hypertension
Smoke
BMI (Kg/m2)
Duration of DM (yrs)
HbA1c (%)
Hypercholesterolemia
Low HDL-cholesterol
Hypertriglyceride
Acute Coronary Syndrome
Medications
Aspirin
ACE inhibitor
Statin
60.3 ± 8.6
88 (75)
41 (35)
47 (40)
25.4 ± 2.9
4.9 ± 4.3
7.8 ± 1.5
43 (36)
43 (36)
32 (27)
62 (53)
118 (100)
29 (25)
34 (29)
60.1 ± 8.9
60 (71)
32 (38)
33 (39)
25.9 ± 3.2
8.9 ± 5.8
8.3 ± 1.7
33 (39)
32 (38)
25 (29)
50 (59)
85 (100)
23 (27)
27 (32)
0.870
0.431
0.462
0.673
0.321
0.001*
0.044*
0.310
0.496
0.452
0.174
1.000
0.545
0.469
Values are n (%) or mean ± SD, ACE indicates angiotensin-converting enzyme; AGEs, advanced glycation end products; BMI, body
mass index; DM, diabetes mellitus; HbA1c, hemoglobin A1c; HDL, high density lipoprotein.
*p < 0.05.
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95% CI, 1.249 - 4.406; p=0.008) and a long lesion
(implanted stent length 24 mm) (OR, 2.496; 95%
CI, 1.283-4.853; p=0.007) were found to be signi-
ficantly associated with angiographic ISR. Al-
though weak correlations were observed with
respect to hypercholesterolemia, low HDL-cho-
lesterol, smoking, and percentage of HbA1c with
development of ISR, none of these factors proved
statistically significant. Moreover, no association
was observed with regard to age, gender, hyper-
tension, obesity, initial event of acute coronary
syndrome, multivessel disease, or complex (B2 or
C) lesions (Table 3).
Table 3. Multivariate Analysis of Risk Factors for In-Stent Restenosis
Risk Factors OR 95% C.I. p value
Age > 55 yrs
Female
Hypertension
Smoking
BMI (< 25 Kg/m2)
HbA1c > 8%
LDL-chol > 160 mg/dl
HDL-chol < 35 mg/dl
Hypertriglyceridemia
Acute Coronary Syndrome
Multivessel Disease
Complex Lesion (B2 or C)
Post MLD ( 3.0 mm)
AGE > 170 U/ml
Long Stent ( 24 mm)
0.544 0.422 - 1.576 0.454
0.564 0.274 - 1.162 0.120
0.602 0.305 - 1.185 0.142
1.868 0.964 - 3.622 0.064
1.336 0.726 - 2.456 0.352
0.919 0.493 - 1.710 0.089
1.728 0.940 - 3.179 0.078
1.701 0.923 - 3.135 0.089
1.431 0.792 - 2.123 0.134
1.644 0.877 - 3.084 0.121
1.096 0.569 - 2.111 0.784
1.133 0.590 - 2.178 0.707
2.346 1.249 - 4.406 0.008*
2.659 1.431 - 4.940 0.002*
2.496 1.283 - 4.853 0.007*
ACS indicates acute coronary syndrome; HDL, high density lipoprotein; ISR, in-stent restenosis; LDL, low density lipoprotein; MLD,
minimal luminal diameter; OR, odds ratio.
*p < 0.05.
Table 2. Angiographic and PCI-Related Data
Level of AGEs (U/ml)
p value
170 (n=148) > 170 (n=115)
Multivessel Disease
Target Vessel
LAD
RCA
LCX
B2 or C target lesion
Stent Length (mm)
Pre-PCI MLD (mm)
Post-PCI MLD (mm)
98 (66)
71 (48)
43 (29)
34 (23)
100 (68)
19.8 ± 5.8
0.8 ± 0.4
3.2 ± 0.4
82 (71)
56 (49)
27 (23)
32 (28)
79 (69)
20.3 ± 5.6
0.7 ± 0.5
3.2 ± 0.4
0.380
0.713
0.321
0.231
0.846
0.561
0.365
0.684
Values are n (%) or mean ± SD. LAD indicates left anterior descending coronary artery; LCX, left circumflex artery; MLD,
minimal luminal diameter; PCI, percutaneous coronary intervention; RCA, right coronary artery.
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DISCUSSION
Diabetes is closely associated with macrovas-
cular disease.11 Its possible mechanism may
involve elevated levels of glucose, resulting in
long-term “memory” in the vessel wall, thereby
augmenting vascular perturbations.12 A recent
report asserted that hyperglycemia leads to the
generation and accumulation of AGEs, and that
their interaction with the receptor for AGE
(RAGE) involves the plausible mechanism of in-
duction of vessel wall memory and sustained
perturbation. These processes culminate in the
progression of atherosclerosis, plaque instability,
and the emergence of clinical symptoms.3
Restenosis and consequent adverse cardiac
events are more frequent in diabetics undergoing
PCI than non-diabetics. This finding may reflect
differences in the nature of restenosis in this
population, as compared with in the nature of
nondiabetic subjects undergoing comparable inter-
ventions. Although a few studies with patients
undergoing PCI with a 6-month angiographic
follow-up have identified a set of clinical and
angiographic predictors of restenosis in diabetes
patients, not all the factors relating to the pro-
bability of restenosis after stent deployment in this
high-risk patients subgroup have yet been estab-
lished.13 Our analysis demonstrates that the angio-
graphic ISR rate at 6-months follow-up was signi-
ficantly elevated in the high serum AGEs group.
Furthermore, our multivariate analysis revealed
that a high level of AGEs is an independent
predictive factor for ISR. Considering the findings
of other studies, a smaller index of the vessel
caliber (assessed by MLD after stenting) and a
long lesion (assessed by stent length) were also
associated with ISR in our study. However, our
data, unlike that of other studies, failed to show
any statistical significance for ISR with regard to
female gender or low BMI. Our data also showed
that the serum levels of AGEs correlated signi-
ficantly with the duration of diabetes and the
level of HbA1c, which reflect recent blood glucose
levels. These findings are compatible with the
concept that the degree of nonenzymatic glycation
is determined largely by glucose concentration
and duration of vascular exposure.
14
It also sug-
gests that the serum level of AGEs can be con-
trolled by strict blood glucose level control. How-
ever, upon multivariate analysis, we found that
the effects of high level HbA1c and long-duration
diabetes were not statistically significant with
regard to the development of ISR. These results
are consistent with the fact that HbA1c is only an
Amadori-type product, and does not appear to
exert direct effects on vascular inflammation or
smooth muscle cell proliferation.
Several recent experimental studies have indi-
cated that AGEs can actively participate in neo-
intimal formation after arterial injury. Zhou et al.
demonstrated significantly increased accumula-
tion of AGEs and increased immunoreactivities of
RAGE and S100/calgranulins in the carotid artery
of diabetic rats in response to balloon injury, as
compared with that of nondiabetic rats.4 Blockage
of the RAGE/ligand interaction significantly at-
tenuated S100-stimulated vascular smooth muscle
cell (VSMC) proliferation in vitro and bromodeo-
xyuridine (BrdU)-labeled proliferating VSMC in
vivo, and suppressed neointimal formation and
increased luminal areas in Zucker rats, both
diabetic and nondiabetic.3 These findings indicate
that RAGE/ligand interaction plays a key role in
neointimal formation after PCI, especially in dia-
betics, and also suggest the plausibility of RAGE
blockade as a therapeutic target in vascular injury,
both in euglycemia and diabetes. According to
other reports, AGEs may, in a receptor-indepen-
dent manner, have a direct impact on the struc-
tural integrity of the vessel wall and underlying
basement membrane. In particular, excessive
cross-linking of matrix molecules such as collagen
may disrupt both cell-matrix and matrix-matrix
interactions.7 AGEs may also exert their patho-
genic effects via the engagement of cellular
binding sites/receptors.8 These results support
our data that the serum levels of AGEs can be
used as an independent predictor for ISR.
AGEs are generated via the polyol pathway. In
this pathway, glucose is reduced to sorbitol by
aldose reductase (AR); fructose generated by this
pathway is converted into fructose-3-phosphate
via the activation of 3-phosphokinase. This, then,
leads to the generation of 3-deoxyglucosone, a
central precursor in the generation of an array of
AGEs, in particular, carboxymethyl-lysine (CML)-
adducts and others.15 Other studies have deter-
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mined that administration of epalrestat (an inhibi-
tor of AR) results in a reduction of the level of
CML adducts and their precursors in erythrocytes
in renal failure.16 According to these results, the
administration of epalrestat in diabetics under-
going PCI may induce a favorable effect on ISR
development. AGE serum levels, then, can clearly
be used as a target guideline for the medical treat-
ment, such as C-reactive protein and lipid profiles,
of diabetics who have undergone PCI. The guid-
ance of medical treatment according to AGE
serum levels may involve strict blood sugar con-
trol and aldose reductase inhibitor administra-
tion. Furthermore, AGE serum levels might con-
stitute an important guideline for medical therapy
and interventional strategy, for example, drug-
eluting stents.
The present study has some limitations, largely
in the fact that the AGE serum levels were mea-
sured only once, just before PCI. A serial follow-
up of AGE levels can provide more accurate
information. However, smooth muscle cell proli-
feration as a cause of in-stent restenosis occurs
mainly in the 3 month immediately after PCI,
whereas serum AGEs have a longer plasma half-
life than that. Therefore, initial AGE serum levels
can be considered to reflect the relatively long
term effects regarding vascular damage and im-
munoinflammatory reactions.
In addition, we did not investigate the patho-
biologic role of increased serum AGEs in neoin-
timal proliferation at the tissue level in our study.
An in vivo tissue study would provide an im-
portant clue regarding the role of AGEs. In spite
of these limitations, our study is, to our knowl-
edge, the first clinical study revealing that the
serum levels of AGEs are good predictors for ISR
in diabetics. In conclusion, high serum AGE levels
are associated with ISR, and constitute an inde-
pendent predictor for ISR in diabetic patients.
Furthermore, serum AGE levels can be used as an
accurate guideline for medical treatment after PCI.
Further investigations are warranted in order to
elucidate the role of AGEs in ISR after PCI.
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